LONDON (Alliance News) - Tiziana Life Sciences PLC on Monday said it completed patient enrollment in a Phase 2a trial of Milciclib in hepatocellular carcinoma.
The company explained that the study is a six-month trial to evaluate the tolerability and anti-tumor activity of its small molecule inhibitor, Milciclib, in liver cancer.
The company expects top line data from the trial in the second quarter of 2019.
Tiziana shares were trading up 6.3% at 67.50 pence each.